Excision BioTherapeutics’ Groundbreaking Gene Therapy for HIV: A Closer Look
Excision BioTherapeutics, a clinical-stage biotechnology company, has recently made headlines with its announcement regarding the publication of pre-clinical data supporting its innovative CRISPR-based gene therapy candidate, EBT-101. This therapy is designed to functionally cure HIV-1. Here’s a detailed summary of the press release: Key Findings: CEO’s Statement: Daniel Dornbusch, the Chief Executive Officer of Excision, […]